Aligos Therapeutics, Inc. Common Stock ALGS
$5.68
+3.46%
at last close
Market Cap$34.28 million
P/E Ratio—
Div Yield—
Volume75.7K
52-Week Range
$3.98$13.69
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $38.50 (+577.8% upside)
Key Stats
- Today's Range
- $5.22 – $6.30
- 50-Day Range
- $3.98 – $7.82
- 52-Week Range
- $3.98 – $13.69
- Volume
- 76K shs
- Average Volume
- 70K shs
- Market Cap
- $34.28 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.08
- Price / Sales
- 1.09
Short Interest
- Short Interest
- 31.30%
- Days to Cover
- 4.10
Financials (TTM)
- Revenue
- $31.52 million
- Net Income
- $-75,962,000
- Net Margin
- -241.01%
- Return on Equity
- -238.24%
- Debt-to-Equity
- —
About Aligos Therapeutics, Inc. Common Stock
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Related Stocks
Compare head-to-head: ALGS vs AMGN·ALGS vs MRNA·ALGS vs HALO·ALGS vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.